: In developing countries like India, the topic of particular concern in healthcare settings are gram negative Multi Drug Resistant (MDR) infections, given the limited number of drugs that are currently available as treatment options for these bacterial infections.

Aim: To assess the anti-microbial and clinical efficacy of CSE-1034 in the treatment of MDR gram negative infections.

Materials and Methods: This retrospective study was conducted on 105 patients suffering from gram negative infections and admitted for treatment at tertiary care centre between February 2014-January 2016. The case-sheets of all those patients resistant to initial empirical therapy and shifted to CSE-1034 alone or in combination were evaluated and analysed.

Results: Microbial sensitivity has shown that isolated pathogens from 76 patients were completely sensitive, 24 were intermediately sensitive and 5 were resistant to CSE-1034. The pattern analysis observed in ICU has shown successful clinical response in 66% patients treated with CSE-1034 and 34% were cured with CSE-1034+Colistin therapy. In IPD, 89% were cured with CSE-1034 whereas, 11% were cured with CSE-1034+Colistin therapy. Multivariate analysis revealed no significant association of therapy dose with the hospitalisation status, pathogen involved, gender or infection type.

Conclusion: Empirical use of CSE-1034 can serve as effective alternative to other drugs for the treatment of MDR Gram negative bacterial infections in both IPD and ICU patients.